# Albuterol to Improve Respiratory Strength in SCI

> **NCT02508311** · PHASE4 · TERMINATED · sponsor: **VA Office of Research and Development** · enrollment: 1 (actual)

## Conditions studied

- Spinal Cord Injury
- Respiratory Muscle Weakness

## Interventions

- **DRUG:** Oral Albuterol Extended Release
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02508311
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06-01
- **Primary completion:** 2022-03-02
- **Final completion:** 2023-02-28
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Our ability to test subjects with tetraplegia in this interventional study was interrupted by the COVID-19 pandemic. Our research pharmacist also informed us that oral albuterol is no longer being manufactured.
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508311, "Albuterol to Improve Respiratory Strength in SCI". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02508311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*